Information in the news releases is current on the date of the announcement, but is subject to change without prior notice.
December 26, 2014
EISAI RECEIVES APPROVAL FOR INDICATION EXPANSION OF PROTON PUMP INHIBITOR PARIET® FOR USE IN PREVENTION OF RECURRENT GASTRIC OR DUODENAL ULCER CAUSED BY LOW-DOSE ASPIRIN THERAPY AND ADDITIONAL 5 MG TABLET FORMULATION IN JAPAN
December 17, 2014
EISAI LISTED FOR 13TH CONSECUTIVE YEAR IN FTSE4GOOD INDEX SERIES, AN INDEX FOR SOCIALLY RESPONSIBLE INVESTMENT
December 10, 2014
EISAI DEMONSTRATES EFFICACY OF INVESTIGATIONAL DUAL OREXIN RECEPTOR ANTAGONIST E2006 IN SLEEP INITIATION AND MAINTENANCE
DATA FROM PHASE Ⅱ CLINICAL TRIAL FOR INSOMNIA PRESENTED AT 53RD AMERICAN COLLEGE OF NEUROPSYCHOPHARMACOLOGY ANNUAL MEETING
December 8, 2014
EISAI PRESENTS RESULTS FROM PHASE Ⅲ TRIAL OF ANTIEPILEPTIC DRUG FYCOMPA® AS ADJUNCTIVE THERAPY FOR PRIMARY GENERALIZED TONIC-CLONIC SEIZURES AT 68TH AMERICAN EPILEPSY SOCIETY ANNUAL MEETING
December 2, 2014
EISAI TO PRESENT NEW RESEARCH ON HALAVEN® (ERIBULIN) AT 37TH ANNUAL SAN ANTONIO BREAST CANCER SYMPOSIUM
December 1, 2014
EISAI SUBMITS MARKETING AUTHORIZATION APPLICATION FOR ANTICANCER AGENT LENVATINIB IN SOUTH KOREA
December 1, 2014
EISAI ESTABLISHES HOLDING COMPANY EISAI CHINA HOLDINGS LTD. IN CHINA
November 28, 2014
EISAI OPENS NEW PARENTERAL FACILITY IN CHINA
November 27, 2014
EISAI OPENS NEW PACKAGING FACILITY AT HATFIELD PRODUCTION PLANT IN U.K.
November 25, 2014
EISAI ANNOUNCES LAUNCH OF ANTICANCER AGENT HALAVEN® AS COMPANY'S FIRST PRODUCT IN BRAZIL
LAUNCH MARKS THE COMMENCEMENT OF BUSINESS IN LATIN AMERICA
November 21, 2014
EISAI LAUNCHES ANTIEPILEPTIC DRUG FYCOMPA® IN HONG KONG
FIRST REGION IN ASIA TO GAIN ACCESS TO NEW FIRST-IN-CLASS THERAPY
November 17, 2014
EISAI'S RANKING SIGNIFICANTLY INCREASES IN THE ACCESS TO MEDICINE INDEX 2014
November 7, 2014
STATEMENT REGARDING THE GERMAN FEDERAL JOINT COMMITTEE'S DECISION ON ANTIEPILEPTIC DRUG FYCOMPA®
November 4, 2014
LORCASERIN MEETS PRIMARY ENDPOINT AND CONFIRMS PROOF-OF-CONCEPT AS POTENTIAL AID FOR SMOKING CESSATION IN INVESTIGATIONAL PHASE Ⅱ CLINICAL STUDY
October 29, 2014
EISAI ANNOUNCES TOP-LINE RESULTS OF INVESTIGATIONAL STUDY ON COADMINISTRATION OF LORCASERIN AND PHENTERMINE
Trial Supports Safety and Tolerability After 12 Weeks of Treatment
October 23, 2014
EISAI SUPPORTS CYCLONE RELIEF EFFORTS IN ANDHRA PRADESH, INDIA
October 21, 2014
U.S. FDA ACCEPTS sNDA FOR ANTIEPILEPTIC AGENT FYCOMPA® AS ADJUNCTIVE TREATMENT OF PRIMARY GENERALIZED TONIC-CLONIC SEIZURES
October 15, 2014
U.S. FDA ACCEPTS EISAI'S sNDA FOR BANZEL® (RUFINAMIDE) AS ADJUNCTIVE TREATMENT IN PEDIATRIC PATIENTS WITH LENNOX-GASTAUT SYNDROME
October 15, 2014
U.S. FDA GRANTS PRIORITY REVIEW STATUS TO NDA FOR ANTICANCER AGENT LENVATINIB
October 14, 2014
U.S. FDA APPROVES ANTIEMETIC AGENT AKYNZEO® FOR PREVENTION OF CHEMOTHERAPY-INDUCED NAUSEA AND VOMITING (CINV)
World’s First Oral Fixed Combination Targeting Two Critical Pathways Involved in CINV
October 1, 2014
EISAI LAUNCHES ANTICANCER AGENT HALAVEN® IN AUSTRALIA
FIRST EXCLUSIVELY MARKETED PRODUCT TO MARK COMMENCEMENT OF FULL-SCALE OPERATIONS
September 30, 2014
PHASE Ⅲ TRIAL OF ARICEPT® IN PATIENTS WITH SEVERE ALZHEIMER'S DISEASE IN CHINA MEETS PRIMARY ENDPOINT
September 26, 2014
EISAI SUBMITS APPLICATION IN JAPAN FOR INDICATION EXPANSION OF VASCULAR EMBOLIZATION DEVICE DC BEAD® TO INCLUDE TREATMENT OF HYPERVASCULARIZED TUMORS AND ARTERIOVENOUS MALFORMATIONS
September 19, 2014
ARICEPT® APPROVED IN JAPAN AS TREATMENT FOR DEMENTIA WITH LEWY BODIES
WORLD'S FIRST TREATMENT FOR BOTH ALZHEIMER'S DISEASE AND DEMENTIA WITH LEWY BODIES
September 18, 2014
EISAI SELECTED SUCCESSIVELY FOR MEMBERSHIP OF DOW JONES SUSTAINABILITY ASIA PACIFIC INDEX 2014
September 17, 2014
EISAI TO PRESENT LATEST CLINICAL DATA ON HALAVEN® (ERIBULIN) AND LENVATINIB AT 39TH ESMO CONGRESS
September 16, 2014
EISAI ENTERS TWO JOINT RESEARCH AGREEMENTS TO DEVELOP NEW ANTIMALARIAL MEDICINES
IN COLLABORATION WITH ST. JUDE CHILDREN'S RESEARCH HOSPITAL, MEDICINES FOR MALARIA VENTURE AND BROAD INSTITUTE
September 10, 2014
EISAI AND KYORIN ENTER INTO AGREEMENT CONCERNING COMPOUND LIBRARY USE FOR THE DEVELOPMENT OF NEW ANTIBACTERIAL AGENTS
September 3, 2014
EISAI'S U.S. SUBSIDIARY EISAI INC. TO DIVEST U.S. RIGHTS FOR ZONEGRAN® TO CONCORDIA PHARMACEUTICALS INC.
August 28, 2014
EISAI INTRODUCES NEW LIFESTYLE INFORMATION WEBSITE “BreCare Garden” FOR PATIENTS WITH BREAST CANCER
INCLUDES INFORMATION ON PATIENT FRIENDLY SPA RESORTS, BEAUTY SALONS AND FASHION ITEMS AVAILABLE IN JAPAN
August 20, 2014
EISAI SUBMITS APPLICATIONS FOR ANTIEPILEPSY AGENT FYCOMPA® SIMULTANEOUSLY IN EUROPE AND U.S. SEEKING INDICATION EXPANSION AS ADJUNCTIVE TREATMENT OF PRIMARY GENERALIZED TONIC-CLONIC SEIZURES
August 18, 2014
EISAI AND ZERIA CONCLUDE LICENSE AGREEMENT CONCERNING A NEW PROTON PUMP INHIBITOR IN JAPAN
August 18, 2014
EISAI SUBMITS MARKETING APPROVAL APPLICATIONS FOR ANTICANCER AGENT LENVATINIB SIMULTANEOUSLY IN EUROPE AND U.S.
August 8, 2014
EISAI ANNOUNCES TOP-LINE PHASE Ⅲ TRIAL RESULTS OF ERIBULIN IN PATIENTS WITH ADVANCED NON-SMALL CELL LUNG CANCER FOLLOWING AT LEAST TWO PRIOR REGIMENS
August 7, 2014
EISAI SUPPORTS EARTHQUAKE RELIEF EFFORTS IN YUNNAN, CHINA
August 1, 2014
EISAI ANNOUNCES PERSONNEL CHANGES FOR ITS CHINESE SUBSIDIARY EISAI CHINA INC. EFFECTIVE AUGUST 1, 2014
August 1, 2014
CONTINUATION OF “POLICY FOR PROTECTION OF THE COMPANY'S CORPORATE VALUE AND COMMON INTERESTS OF SHAREHOLDERS (SHAREHOLDER RIGHTS PLAN)”
July 31, 2014
EMA ACCEPTS EISAI'S REQUEST FOR ACCELERATED ASSESSMENT OF ANTICANCER AGENT LENVATINIB
LEADING TOWARD SUBMISSION FOR APPROVAL IN EUROPE
July 3, 2014
EISAI RECEIVES EUROPEAN COMMISSION APPROVAL OF INDICATION EXPANSION FOR ANTICANCER AGENT HALAVEN® FOR ADVANCED BREAST CANCER AFTER ONLY ONE PRIOR CHEMOTHERAPY
July 2, 2014
EISAI TO LAUNCH FIRST CHOCOLA BB BRAND PRODUCT “CHOCOLA BB® ROYAL DRINK” IN CHINA
June 26, 2014
EISAI SUBMITS FIRST MARKETING AUTHORIZATION APPLICATION FOR ANTICANCER AGENT LENVATINIB IN JAPAN
June 25, 2014
LAUNCH OF TYPE IV COLLAGEN MEASUREMENT REAGENT KIT “PANASSAY® IV-C [LATEX]” IN JAPAN
June 17, 2014
PHASE Ⅲ TRIAL OF ANTIEPILEPTIC DRUG FYCOMPA® (PERAMPANEL) MEETS PRIMARY ENDPOINTS AS ADJUNCTIVE THERAPY IN PATIENTS WITH UNCONTROLLED PRIMARY GENERALIZED TONIC-CLONIC SEIZURES
June 2, 2014
EISAI PRESENTS DATA ON HALAVEN® FROM POOLED ANALYSIS OF OVER 1,800 ADVANCED BREAST CANCER PATIENTS AT 50TH ASCO ANNUAL MEETING
SIGNIFICANT IMPROVEMENT IN OVERALL SURVIVAL FOUND IN HER2 NEGATIVE AND TRIPLE NEGATIVE BREAST CANCER PATIENTS
May 31, 2014
LENVATINIB PHASE Ⅲ RESULTS SHOW SIGNIFICANT IMPROVEMENT IN PROGRESSION-FREE SURVIVAL IN PATIENTS WITH RADIOIODINE-REFRACTORY DIFFERENTIATED THYROID CANCER
Phase Ⅲ data for lenvatinib to be presented in a Head and Neck Cancer oral session at ASCO
May 30, 2014
EISAI HONORED WITH PRESTIGIOUS ‘UCL ENTERPRISE PARTNER OF THE YEAR 2014’ AWARD BY UNIVERSITY COLLEGE LONDON (UCL)
For Outstanding Contribution to Neuroscience Research and Entrepreneurship
May 29, 2014
ANTIEMETIC AGENT ALOXI® APPROVED FOR CHILDREN BY THE U.S. FDA
U.S. MARKET EXCLUSIVITY EXTENDED BY SIX MONTHS TO OCTOBER 13, 2015
May 27, 2014
EISAI TO LAUNCH CHOCOLA BB® SPARKLING SALTY NATSUMIKAN FLAVOR
CONTAINS 5 INGREDIENTS THAT HELP BRING OUT THE BEAUTY FROM WITHIN & SODIUM SUPPLEMENT
May 27, 2014
EISAI RECEIVES POSITIVE OPINION FROM EMA'S CHMP ON EXPANDING INDICATION OF ANTICANCER AGENT HALAVEN® FOR USE IN EARLIER-LINE TREATMENT OF ADVANCED BREAST CANCER
May 26, 2014
KAN RESEARCH INSTITUTE COMMENCES FULL-SCALE OPERATION AT NEW FACILITY
AIMS TO DISCOVER AND DEVELOP NEW BIOLOGIC THERAPIES IN KANSAI INTERNATIONAL STRATEGIC INNOVATION ZONE
May 15, 2014
EISAI TO PRESENT NEW RESEARCH ON ONCOLOGY PRODUCTS AND PIPELINE AT 50TH ASCO ANNUAL MEETING
HIGHLIGHTS INCLUDE NEW PHASE Ⅲ CLINICAL DATA ON INVESTIGATIONAL ANTICANCER AGENT LENVATINIB IN RADIOIODINE-REFRACTORY DIFFERENTIATED THYROID CANCER
May 12, 2014
EISAI RESUBMITS ANTIEPILEPTIC DRUG FYCOMPA® TO GERMAN FEDERAL JOINT COMMITTEE FOR ADDITIONAL BENEFIT ASSESSMENT
May 9, 2014
EISAI EXPANDS COLLABORATION WITH BIOGEN IDEC TO DEVELOP AND COMMERCIALIZE NEXT GENERATION ALZHEIMER'S DISEASE TREATMENTS TO INCLUDE JAPAN
May 7, 2014
EISAI AND UNIVERSITY OF TSUKUBA INITIATE JOINT INDUSTRY-ACADEMIA DEVELOPMENT OF NOVEL INFLAMMATORY BOWEL DISEASE TREATMENT USING NEW BIOMARKERS
April 24, 2014
“EISAI ACCESS TO MEDICINES (ATM) NAVIGATOR” EISAI LAUNCHES NEW COMPREHENSIVE INFORMATION WEBSITE ABOUT NEGLECTED TROPICAL DISEASES AND ELIMINATION INITIATIVES
April 15, 2014
EISAI CEO HARUO NAITO APPOINTED KNIGHT COMMANDER OF BRITISH EMPIRE
April 7, 2014
EISAI LAUNCHES NEW ENERGY DRINK “JOMA®”
“CAST A SPELL OF HAPPINESS”
March 31, 2014
U.S. SUBSIDIARY EISAI INC. ASSIGNS WORLDWIDE RIGHTS FOR DNA METHYLATION INHIBITOR DACOGEN® TO OTSUKA
March 28, 2014
Notice Concerning Shelf Registration for Issuance of Stock Options
March 25, 2014
Notice Concerning Voluntary Adoption of International Financial Reporting Standards (IFRS)
March 20, 2014
EISAI ENTERS COLLABORATION WITH LIVERPOOL SCHOOL OF TROPICAL MEDICINE AND UNIVERSITY OF LIVERPOOL TO DISCOVER NOVEL ANTI-WOLBACHIA TARGETED ANTI-FILARIAL DRUGS
JOINT RESEARCH PROJECT AWARDED GHIT FUND GRANT
March 5, 2014
EISAI AND BIOGEN IDEC ENTER COLLABORATION TO DEVELOP AND COMMERCIALIZE ALZHEIMER'S DISEASE TREATMENTS
Agreement to Enhance R&D Capabilities and Pipeline Aimed at Creating New Therapies to Suppress Alzheimer's Disease Progression
February 13, 2014
EISAI ANNOUNCES LAUNCH OF PARIET® TRIPLE FORMULATION COMBINATION PACKS RABECURE® 400 AND 800 AND RABEFINE®, FOR PRIMARY AND SECONDARY H. PYLORI ERADICATION RESPECTIVELY, IN JAPAN
February 3, 2014
PHASE Ⅲ TRIAL SHOWS LENVATINIB MEETS PRIMARY ENDPOINT OF PROGRESSION FREE SURVIVAL BENEFIT IN TREATMENT OF RADIOIODINE-REFRACTORY DIFFERENTIATED THYROID CANCER
February 3, 2014
EISAI ANNOUNCES LAUNCH OF VASCULAR EMBOLIZATION DEVICE DC BEAD® IN JAPAN
February 3, 2014
Notification Regarding Results of Voluntary Retirement Program
January 27, 2014
EISAI LISTED IN GLOBAL 100 SUSTAINABILITY INDEX FOR SECOND CONSECUTIVE YEAR
January 22, 2014
EISAI ANNOUNCES LAUNCH OF NEW “CRYSTAL VEIL® MASK BOKIN 24 MINT” FACE MASK SPRAY CONTAINING LONG-ACTING ANTIMICROBIAL AGENT ETAK®
24-HOUR PROTECTION FROM POLLEN, VIRUSES & BACTERIA ADHERING TO FACE MASKS
January 6, 2014
EISAI ANNOUNCES LAUNCH OF ANTIEPILEPTIC DRUG FYCOMPA™ IN U.S.
